Search By:
Products
Injury
Topic
Company
Industry
Johnson & Johnson's Procit might increase risk of death and rapid tumor growth.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topic
- Increased Risk of Bodily Injury
Product or Service
- Procit
Injury Types
- Death
- Breast Cancer
- Cervical Cancer
- Accelerated Rate of Tumor Growth
Investigation Details
Procit is an Erythropoiesis Stimulating Agents (ESAs). ESAs are used to treat the blood-disorder anemia in patients with kidney failure or who are undergoing chemotherapy. The Food and Drug Administration warn that this class of drugs increase death and accelerate tumor growth in patients with several types of cancer, including breast and cervical. Prior labeling added to the drugs in November warned of similar risks in other types of cancers. The warnings apply to drugmaker Amgen's Aranesp and Epogen, as well as Procit, sold by Johnson & Johnson. Labeling approved by FDA said risks occurred when doctors treated patients with elevated levels of the drugs, which stimulate red blood cell levels.
Do not change medications without first consulting your doctor.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Johnson & Johnson (JNJ) | Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. |